New combo therapy shows promise for lung cancer brain metastases

NCT ID NCT04768075

Completed Disease control Sponsor: Guangdong Association of Clinical Trials Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether adding the immunotherapy drug camrelizumab to standard chemotherapy and radiation helps people with advanced lung cancer whose disease has spread to the brain. The trial included 60 patients who had not received chemotherapy before. Researchers measured how long it took for brain tumors to grow or for patients to die, comparing the camrelizumab combination to a placebo combination.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Camrelizumab (an immunotherapy drug) combined with chemotherapy (cisplatin/carboplatin plus pemetrexed, paclitaxel, or nab-paclitaxel) and possibly radiation therapy (SRT or WBRT)
What this could lead to: If successful, this combination could offer a new treatment option that delays brain tumor growth and improves survival for people with advanced lung cancer that has spread to the brain.
What could go wrong: This is a completed Phase 3 trial with only 60 participants, so results may not apply to all patients. Immunotherapy can cause immune-related side effects, and the addition of radiation may increase toxicity.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-SMALL CELL LUNG CANCER

Contacts and locations

Show contact details

Locations

Affiliated Hangzhou Cancer Hospital, Zhejiang University School of Medicine

Hangzhou, Zhejiang, China
Affiliated Hospital of Hebei University / School of Clinical Medicine

Baoding, Hebei, China
Affiliated Tumor Hospital of Guangxi Medical University

Nanning, China
Beijing Cancer Hospital

Beijing, Beijing Municipality, China
Binzhou Medical University Hospital

Binzhou, Shandong, China
Fujian Cancer Hospital

Fujian, Fuzhou, China
Guangdong General Hospital

Guangzhou, Guangdong, 510080, China
The First Affiliated Hospital of Guangxi Medical University

Nanning, Guangxi, China
The First Affiliated Hospital of Guangzhou Medical University

Guangzhou, Guangdong, China
The First Affiliated Hospital of Guangzhou University of Chinese Medicine

Guangzhou, Guangdong, China
The First Affiliated Hospital of Xi'an Jiaotong University

Xi’an, Shanxi, China
The Second Affiliated Hospital of Nanchang University

Nanchang, Jiangxi, China
Tongji Medical College, Huazhong University of Science and Technology

Wuhan, Hubei, China
Zhongda Hospital Southeast University

Nanjing, Jiangsu, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.